Literature DB >> 10975158

Dentistry's role in the diagnosis and co-management of patients with sleep apnoea/hypopnoea syndrome.

A H Friedlander1, I K Friedlander, M A Pogrel.   

Abstract

The sleep apnoea/hypopnoea syndrome (SAHS) is characterized by repeated upper airway narrowing or collapse during sleep. The obstruction is caused by the soft palate and/or base of tongue collapsing against the pharyngeal walls because of decreased muscle tone. These episodes are accompanied by hypoxaemia, surges in blood pressure, brief arousal from sleep and pronounced snoring. Individuals with occult disease are at heightened risk of motorway accidents because of excessive sleepiness, sustained hypertension, myocardial infarction, and stroke. The signs and symptoms of SAHS may be recognisable in the dental practice. Common findings in the medical history include daytime sleepiness, snoring, hypertension, and type 2 diabetes mellitus. Common clinical findings include male gender, obesity, increased neck circumference, excessive fat deposition in the palate, tongue (macroglossia) and pharynx, a long soft palate, a small recessive mandible and maxilla, and calcified carotid artery atheromas on panoramic and lateral cephalometric radiographs. Dentists who recognise these signs and symptoms have an opportunity to diagnose patients with occult SAHS. After confirmation of the diagnosis by a physician, dentists can participate in the management of the disorder by fabricating mandibular advancement appliances that enlarge the retroglossal space by anterior displacement of the tongue and performing corrective upper airway surgery that prevents recurrent airway obstruction.

Entities:  

Mesh:

Year:  2000        PMID: 10975158     DOI: 10.1038/sj.bdj.4800687

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  1 in total

Review 1.  Sleep bruxism: an overview for clinicians.

Authors:  H Beddis; M Pemberton; Stephen Davies
Journal:  Br Dent J       Date:  2018-09-21       Impact factor: 1.626

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.